[go: up one dir, main page]

AR019947A1 - Metodo para tratar o prevenir trastornos causados por disfunciones de la motilidad intestinal en seres humanos y composiciones farmaceuticas de aplicacionen dicho metodo - Google Patents

Metodo para tratar o prevenir trastornos causados por disfunciones de la motilidad intestinal en seres humanos y composiciones farmaceuticas de aplicacionen dicho metodo

Info

Publication number
AR019947A1
AR019947A1 ARP990103729A ARP990103729A AR019947A1 AR 019947 A1 AR019947 A1 AR 019947A1 AR P990103729 A ARP990103729 A AR P990103729A AR P990103729 A ARP990103729 A AR P990103729A AR 019947 A1 AR019947 A1 AR 019947A1
Authority
AR
Argentina
Prior art keywords
dysfunctions
treat
applying
pharmaceutical compositions
human beings
Prior art date
Application number
ARP990103729A
Other languages
English (en)
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AR019947A1 publication Critical patent/AR019947A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se trata de composiciones que emplean métodos donde se utilizan el isomero de norcisaprida puro (+). Se ha hallado sorprendentemente que este compuestoresulta ser una droga potente para el tratamiento de trastornos del sistema nervioso central. Seha hallado también que el compuesto, norcisaprida (+) resultaser un potente agente antiemético. Finalmente, el isomero de norcisaprida (+) evita también ciertos efectos secundarios adversos y ciertas interacciones dedroga adversas.
ARP990103729A 1998-07-28 1999-07-28 Metodo para tratar o prevenir trastornos causados por disfunciones de la motilidad intestinal en seres humanos y composiciones farmaceuticas de aplicacionen dicho metodo AR019947A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/123,892 US6147093A (en) 1996-07-19 1998-07-28 Methods for treating gastroesophageal reflux disease

Publications (1)

Publication Number Publication Date
AR019947A1 true AR019947A1 (es) 2002-03-27

Family

ID=22411520

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103729A AR019947A1 (es) 1998-07-28 1999-07-28 Metodo para tratar o prevenir trastornos causados por disfunciones de la motilidad intestinal en seres humanos y composiciones farmaceuticas de aplicacionen dicho metodo

Country Status (25)

Country Link
US (4) US6147093A (es)
EP (1) EP1100502A1 (es)
JP (1) JP2002521448A (es)
KR (1) KR20010071047A (es)
CN (1) CN1320036A (es)
AR (1) AR019947A1 (es)
AU (1) AU5126099A (es)
BG (1) BG105218A (es)
BR (1) BR9912581A (es)
CA (1) CA2338465A1 (es)
CO (1) CO5060499A1 (es)
CZ (1) CZ295776B6 (es)
EA (1) EA200100188A1 (es)
EE (1) EE200100051A (es)
HK (1) HK1041226A1 (es)
HR (1) HRP20010075A2 (es)
HU (1) HUP0102979A3 (es)
ID (1) ID28894A (es)
IL (1) IL141047A0 (es)
NO (1) NO20010464L (es)
NZ (1) NZ509671A (es)
PL (1) PL345764A1 (es)
SK (1) SK1202001A3 (es)
TR (1) TR200100921T2 (es)
WO (1) WO2000006165A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
AU757077B2 (en) * 1997-07-11 2003-01-30 Janssen Pharmaceutica N.V. (+)-norcisapride useful for 5-HT3 and 5-HT4 mediated disorders
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
DE10314916A1 (de) 2003-04-01 2004-10-21 Endress + Hauser Flowtec Ag, Reinach Vorrichtung zur Bestimmung und/oder Überwachung des Volumen- und/oder Massenstroms eines Mediums
DK1701951T3 (da) * 2003-12-23 2010-06-07 Serodus As Modulatorer af perifere 5-HT receptorer
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
JP5200288B2 (ja) * 2004-01-07 2013-06-05 アルメテオン、インコーポレイテッド 胃腸疾患および中枢神経系疾患の治療のための立体異性体化合物と方法
US20050160544A1 (en) * 2004-01-26 2005-07-28 Marc Geller Contoured grill brush
KR101351454B1 (ko) * 2005-08-31 2014-01-14 아메데온, 인코포레이티드 위장 및 중추 신경계 장애의 치료에 유용한 입체이성질체 화합물의 합성 방법 및 중간 생성물
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
EP1170010A3 (en) * 1992-07-07 2004-05-19 Sepracor Inc. Method of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
WO1994001112A1 (en) * 1992-07-07 1994-01-20 Sepracor Inc. Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
WO1995001803A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
AU757077B2 (en) * 1997-07-11 2003-01-30 Janssen Pharmaceutica N.V. (+)-norcisapride useful for 5-HT3 and 5-HT4 mediated disorders

Also Published As

Publication number Publication date
HUP0102979A3 (en) 2002-01-28
NZ509671A (en) 2003-08-29
ID28894A (id) 2001-07-12
US20040044039A1 (en) 2004-03-04
EE200100051A (et) 2002-06-17
PL345764A1 (en) 2002-01-02
US6147093A (en) 2000-11-14
AU5126099A (en) 2000-02-21
US6632827B2 (en) 2003-10-14
EP1100502A1 (en) 2001-05-23
BR9912581A (pt) 2001-05-02
HRP20010075A2 (en) 2002-02-28
IL141047A0 (en) 2002-02-10
CZ295776B6 (cs) 2005-11-16
NO20010464L (no) 2001-03-23
CN1320036A (zh) 2001-10-31
US6242465B1 (en) 2001-06-05
JP2002521448A (ja) 2002-07-16
TR200100921T2 (tr) 2001-10-22
US20010020031A1 (en) 2001-09-06
CA2338465A1 (en) 2000-02-10
NO20010464D0 (no) 2001-01-26
KR20010071047A (ko) 2001-07-28
CO5060499A1 (es) 2001-07-30
EA200100188A1 (ru) 2001-08-27
HK1041226A1 (zh) 2002-07-05
BG105218A (en) 2001-11-30
SK1202001A3 (en) 2001-08-06
CZ2001348A3 (cs) 2002-01-16
WO2000006165A1 (en) 2000-02-10
HUP0102979A2 (hu) 2001-12-28

Similar Documents

Publication Publication Date Title
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
AR019947A1 (es) Metodo para tratar o prevenir trastornos causados por disfunciones de la motilidad intestinal en seres humanos y composiciones farmaceuticas de aplicacionen dicho metodo
NO20030724L (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
SV1998000029A (es) Compuestos de pirazina ref. pg3186
CR6210A (es) Composiciones de celecoxib
ECSP941122A (es) Derivados de 5-arilindoles
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
PA8484301A1 (es) Formulaciones farmaceuticas de liberacion controlada
PT1014961E (pt) Tratamento da cefaleia de enxaqueca utilizando metoclopramida e um nsaid
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
UY26130A1 (es) Compuestos para tratar la obesidad
BR9708287A (pt) Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêutica
ES2176343T3 (es) Composiciones sanadoras de tratamiento de heridas causadas por el acne que contienen un piruvano, un antioxidante y una mezcla de acidos grasos.
RU94002337A (ru) Фармацевтическая композиция, применение гамма-линоленовой или дигомо-гамма-линоленовой кислоты для лечения поражений после облучения, способ лечения
ES2136252T3 (es) Tratamiento de enfermedades causadas por trastornos de la glandula sebacea mediante el uso de inhibidores de acil coa colesterol acil transferasa.
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
ES2188582T3 (es) El uso de ranitidina-citrato de bismuto en combinacion con claritromicina o claritromicina y tetraciclina en la fabricacion de un medicamento para tratar trastornos gastrointestinales.
IT1212896B (it) Metodo di somministrazione per via inalatoria di gangliosidi e derivati, e composizioni farmaceutiche relative
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
ES2189956T3 (es) Derivados de quinolina, procedimientos para su preparacion y su uso como medicamentos.
MX9300558A (es) Nueva sulfonilurea, procedimiento para su preparacion y formulado farmaceutico que la contiene.
ES2130506T3 (es) Uso de 5-acil-1,4-dihidropiridinas para tratamiento de enfermedades del snc.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal